PhaseBio to Present at the Jefferies 2013 Global Healthcare Conference

<0> PhaseBio Pharmaceuticals, Inc.Anne Erickson, 858-699-9166 </0>

PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company focused on diabetes, will present at the Jefferies 2013 Global Healthcare Conference in New York on Wednesday, June 5, 2013 at 12:30 p.m. ET. Jonathan P. Mow, chief business officer, PhaseBio, will present a Company overview. A copy of the presentation will be available on the Company’s website at  shortly afterwards.

PhaseBio is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes, metabolic and cardiovascular disease. The Company’s proprietary platform technology uses elastin-like biopolymers (ELPs) to control the half-life, bioavailability and physical characteristics of the molecule for ease of administration. The resulting drug products are tuned for a specific rate of absorption, thereby potentially increasing efficacy and reducing side effects. The Company’s lead development candidates are PB1023, a once-weekly GLP-1 analogue for type 2 diabetes; PE0139, a novel basal insulin ELP-fusion; and Vasomera, a weekly vasoactive intestinal peptide (VIP) agonist for acute and chronic heart failure and pulmonary arterial hypertension. PhaseBio is privately owned with headquarters and research laboratories in Malvern, Pennsylvania.

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.